deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT03057600

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

Sponsor: Calithera Biosciences, Inc

Conditions TNBC - Triple-Negative Breast Cancer Triple Negative Breast Cancer
Interventions CB-839 Paclitaxel
Updated 17 times since 2017 Last updated: Sep 19, 2022 Started: May 1, 2017 Primary completion: Nov 25, 2019 Completion: Nov 25, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates TNBC - Triple-Negative Breast Cancer and Triple Negative Breast Cancer and is currently completed. Calithera Biosciences, Inc leads this study, which shows 17 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2017 – ~Aug 2017 · 5 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Feb 2020 · 11 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2022 — Sep 2022 [monthly]

    Completed PHASE2

▶ Show 12 earlier versions

  1. Sep 2021 — Apr 2022 [monthly]

    Completed PHASE2

  2. Mar 2021 — Sep 2021 [monthly]

    Completed PHASE2

  3. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE2

  4. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Mar 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  8. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  9. Dec 2017 — May 2018 [monthly]

    Recruiting PHASE2

  10. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  11. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Mar 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Calithera Biosciences, Inc
Data source: Calithera Biosciences, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, United States , Atlanta, United States , Baltimore, United States , Birmingham, United States , Charleston, United States , Detroit, United States , Germantown, United States , Greenville, United States , Hackensack, United States , Houston, United States and 13 more locations